Core Viewpoint - Viatris Inc. has announced a 2026 dividend policy of $0.48 per share and a quarterly dividend of $0.12, marking the sixth consecutive year of dividend payments [1] Company Overview - Viatris is a global healthcare company that aims to bridge the gap between generics and brand-name drugs, providing access to high-quality medicines for approximately 1 billion patients annually [1] - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India [1] Dividend Announcement - The Board of Directors approved a dividend policy of $0.48 per share for 2026 and declared a quarterly dividend of $0.12 per share [1] - The dividend is scheduled to be paid on March 18, 2026, to shareholders of record as of March 9, 2026 [1]

FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia [Accessibility Statement] Skip NavigationFDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- [Viatris Inc.](Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for MR-141 (phentolamine ophthalmic solution 0.75%) fo ...

The upcoming report from Viatris (VTRS) is expected to reveal quarterly earnings of $0.52 per share, indicating a decline of 3.7% compared to the year-ago period. Analysts forecast revenues of $3.52 billion, representing a decline of 0.3% year over year.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.6% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ear ...

Group 1 - The article initiates coverage of Viatris (VTRS), a global player in the generic pharmaceutical sector, formed in 2020 through the merger of Mylan and Pfizer's Upjohn division [1] Group 2 - The company operates in developed markets and focuses on fundamental, income-oriented, long-term analysis [2] - Analysts have disclosed a beneficial long position in VTRS shares, indicating confidence in the company's performance [3]

Core Viewpoint - EyePoint, Inc. has appointed Michael Campbell as Chief Commercial Officer to lead the commercial strategy and launch readiness for DURAVYU, an investigational treatment for retinal diseases currently in Phase 3 development [1][2] Company Overview - EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics for serious retinal diseases, with its lead product candidate DURAVYU expected to provide significant commercial potential [8][9] - The company is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts [9] Leadership Appointment - Michael Campbell brings over 30 years of commercial leadership experience, having successfully launched several ophthalmology products, including Lucentis and Xiidra [1][3][4] - His previous roles include Chief Commercial Officer at Opthea and Senior Vice President at Viatris Eye Care, where he led the launch of Tyrvaya [3][4] Product Development - DURAVYU is currently in Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), with topline data expected in mid-2026 [8][10] - The product is designed as a sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, and is positioned to potentially be the first sustained release TKI to market [2][8] Commercial Strategy - The company aims to leverage Campbell's expertise to position DURAVYU for a successful U.S. launch, emphasizing a patient-centric approach and robust clinical data [2][8] - DURAVYU is expected to address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME, enhancing its potential market impact [10]

Core Insights - Nxera Pharma reported a disciplined execution and strategic progress in 2025, focusing on building a resilient biopharmaceutical business with a growing commercial presence in Japan and a maturing pipeline [2][3] Operational Highlights - PIVLAZ® sales in Japan increased, establishing it as the standard of care for preventing cerebral vasospasm, with market share rising from 69% in 2024 to 74% in 2025 [6] - Q4 2025 net sales for PIVLAZ® reached JPY 4,545 million (US$30.4 million), while FY 2025 net sales totaled JPY 13,511 million (US$90.3 million), reflecting a 6.8% growth compared to FY 2024 [6][17] - QUVIVIQ™ achieved FY 2025 net sales of JPY 4,327 million (US$28.9 million), marking a significant 223.9% growth from FY 2024 [7][17] - The company regained full rights to its GPR52 agonist program and plans to explore strategic opportunities for this asset [9] Financial Performance - Total revenue for FY 2025 was JPY 29,615 million (US$197.9 million), an increase of JPY 780 million (US$5.2 million) from the previous year [17] - R&D expenses rose to JPY 14,466 million (US$96.7 million), reflecting increased investment in clinical-stage pipelines and the obesity and metabolic disease area [17] - Operating loss for FY 2025 was JPY 8,462 million (US$56.5 million), compared to a loss of JPY 5,423 million (US$35.9 million) in the prior year [17] - Net loss totaled JPY 12,530 million (US$83.7 million), up from a loss of JPY 4,838 million (US$32.0 million) in the previous year [23] Strategic Initiatives - Nxera implemented a focused restructuring to enhance its path to profitability, concentrating resources on high-potential programs and reducing operating expenses [8] - The establishment of a Metabolic Advisory Council aims to provide guidance as Nxera advances its pipeline targeting obesity and metabolic disorders [11] - The company plans to submit a marketing authorization application for daridorexant in South Korea in Q1 2026, with approval expected in Q1 2027 [10]

Core Viewpoint - Viatris Inc. will report its fourth quarter and full year 2025 financial results on February 26, 2026, with a subsequent webcast for discussion [1] Group 1: Financial Reporting - The financial results will be discussed in a webcast hosted by company executives at 8:30 a.m. ET on the reporting date [1] - Investors and the public can access the live webcast through the company's investor website or by phone [2] Group 2: Investor Events - An Investor Event is scheduled for March 19, 2026, in New York City, with more details to be provided during the February investor call [2] - Analysts and institutional investors will receive separate invitations to pre-register for the event [3] Group 3: Company Overview - Viatris is a global healthcare company that combines generics and brand medications to address healthcare needs [4] - The company aims to empower people to live healthier lives, providing access to high-quality medicines for approximately 1 billion patients annually [4] - Viatris has a diverse portfolio and a global supply chain, with headquarters in the U.S. and centers in Pittsburgh, Shanghai, and Hyderabad [4]

Core Viewpoint - Viatris Inc. announces the appointment of Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, following the transition of Brian Roman, who has served the company for over 20 years [1][2]. Group 1: Leadership Transition - Brian Roman will remain as an advisor through April 1, 2026, to ensure a smooth transition [1]. - Matthew J. Maletta brings nearly 30 years of legal experience, having previously served as Executive Vice President and Chief Legal Officer at Endo [3]. - Maletta's past experience includes over a decade at Allergan, where he was involved in significant transactions, including the $70 billion sale of Allergan to Actavis [4]. Group 2: Company Statements - Viatris CEO Scott A. Smith expressed gratitude for Brian Roman's leadership and highlighted the strength of the internal legal and compliance teams [5]. - Maletta expressed enthusiasm about joining Viatris at a pivotal time and looks forward to contributing to the company's future [5]. - Roman reflected on his experiences and accomplishments during his tenure, emphasizing the importance of the internal legal and compliance teams [5]. Group 3: Company Overview - Viatris Inc. is a global healthcare company that aims to bridge the gap between generics and branded pharmaceuticals, providing access to high-quality medicines for approximately 1 billion patients annually [6]. - The company is headquartered in the U.S. with global centers in Pittsburgh, Shanghai, and Hyderabad, India [7].

Company Overview - Aquestive Therapeutics, Inc. (NASDAQ:AQST) is a pharmaceutical company focused on developing and commercializing innovative products to address unmet medical needs, specializing in oral film-based drug delivery systems [2][4] - Competitors include Teva Pharmaceuticals and Viatris, which also focus on drug delivery technologies [2] Recent Developments - New Street set a price target of $12 for AQST, indicating a potential upside of approximately 193% from its trading price of $4.10 [3] - Despite receiving a Complete Response Letter (CRL) from the FDA for Anaphylm, AQST's stock has increased by 38.98%, rising by $1.15 [3][4] - The CRL highlighted deficiencies in the human factors validation study, temporarily halting discussions on labeling and post-marketing commitments [4] - AQST's stock has shown volatility, with a daily trading range between $3.79 and $4.39, and has fluctuated between a high of $7.55 and a low of $2.12 over the past year [4] Market Position - AQST's market capitalization stands at approximately $500.21 million, with a trading volume of 60.81 million shares on the NASDAQ exchange [4] - The outcome of discussions to address the FDA's concerns regarding Anaphylm is crucial for the company's future, as it represents a significant opportunity in the treatment of anaphylaxis [5]

Core Insights - Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) is recognized as a rapidly growing penny stock, with analysts highlighting its potential for investment [1] - Citi analyst Yigal Nochomovitz raised the price target for Lexicon from $1.90 to $2.10, maintaining a Buy rating due to an updated financial model reflecting milestones in the LX9851 partnership with Novo Nordisk [1][3] Financial Performance - In Q3 2025, Lexicon reported revenue of $14.2 million, primarily driven by $13.2 million in licensing revenue from its partnership with Novo Nordisk [2] - The company's net loss decreased to $12.8 million, or $0.04 per share, compared to a net loss of $64.8 million in the previous year [2] Research and Development Milestones - Lexicon achieved significant R&D milestones, including the completion of all IND-enabling studies for its obesity candidate LX9851, which have been submitted to Novo Nordisk for clinical development [3] - The company is advancing its heart failure medication, INPEFA, into international markets through licensee Viatris and has submitted additional data to the FDA to support the benefit-risk profile for Zynquista in type 1 diabetes [3]